Effect of Positive Bone Marrow EBV In situ Hybridization in Staging and Survival of Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal-Type

• Published in: Clinical cancer research Vol. 13; no. 11; pp. 3250 - 3254
• Main Authors: Lee, Jeeyun, Suh, Cheolwon, Huh, Jooryung, Jun, Hyun Jung, Kim, Kihyun, Jung, Chulwon, Park, Keunchil, Park, Yeon Hee, Ko, Young Hyeh, Kim, Won Seog
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.2007
• Subjects: Aged; Antineoplastic agents; Biological and medical sciences; Bone Marrow - virology; Bone Marrow Cells - metabolism; CD3 Complex - biosynthesis; Epstein-Barr virus; Epstein-Barr Virus Infections - complications; Female; Hematologic and hematopoietic diseases; Herpesvirus 4, Human - metabolism; Humans; In Situ Hybridization; Killer Cells, Natural - metabolism; Killer Cells, Natural - virology; Leukemias and lymphomas; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphoma, T-Cell - mortality; Lymphoma, T-Cell - virology; Male; Medical sciences; Middle Aged; Nasopharyngeal Neoplasms - mortality; Nasopharyngeal Neoplasms - virology; Neoplasm Staging - methods; Pharmacology. Drug treatments; Gammaherpesvirinae; Natural killer T cell; Lymph node; Staging; Herpesviridae; In situ; Stage classification; Early stage; Malignant hemopathy; Epstein Barr virus; Intranasal administration; Hybridization; Lymphoid neoplasm; Lymphoma; Survival; Infection; Virus; Lymphoproliferative syndrome; Nose; Viral disease; Bone marrow; Localized
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-06-2373

Purpose: The aim of the study was to determine the effect of EBV-encoded RNA-1 in situ hybridization (EBER-1 ISH) in bone marrow specimens on survival outcome in patients with clinical stage I/II natural killer/T-cell lymphoma. Experimental Design: We systematically did EBER-1 ISH on 182 archival bone marrow tissues from 91 patients who were diagnosed of stage I/II natural killer/T-cell lymphoma and analyzed the correlation between bone marrow EBER-1 ISH status and survival. We defined minimal bone marrow involvement and definite bone marrow involvement to distinguish the subgroups who revealed EBV-positive cells from normal marrow by EBER-1 ISH from those who showed typical neoplastic cells in bone marrow biopsies. Results: In total, 17 of the 91 (18.7%) patients showed positivity for EBER-1 ISH at least in one of the bilateral bone marrow biopsies with 14 minimal bone marrow involvements and 3 definite bone marrow involvements. Patients with positive bone marrow EBER-1 ISH showed significantly poorer overall survival than those who were negative for bone marrow EBER-1 ISH (median survival, 16.1 months versus not reached; P = 0.045). Conclusion: Considering a high proportion of stage I/II patients (15.4%) with minimal in bone marrow specimens, bone marrow EBER-1 ISH should be routinely done in all patients with localized disease for more accurate staging.